List of Excipients in Branded Drug BUPRENORPHINE HCL

Generic Drugs Containing BUPRENORPHINE HCL

Company	Ingredient	NDC	Excipient
SpecGx LLC	buprenorphine hcl	0406-7012	ANHYDROUS CITRIC ACID
SpecGx LLC	buprenorphine hcl	0406-7012	LACTOSE MONOHYDRATE
SpecGx LLC	buprenorphine hcl	0406-7012	MANNITOL
SpecGx LLC	buprenorphine hcl	0406-7012	POVIDONE

What are the Most Frequently-Used Excipients in BUPRENORPHINE HCL?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
10	ANHYDROUS CITRIC ACID
1	BUTYLATED HYDROXYANISOLE
9	CROSPOVIDONE

Buprenorphine HCl Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 16, 2026

Buprenorphine HCl is a high-value opioid-dependence active pharmaceutical ingredient with established sublingual, buccal, transdermal, implantable, and injectable delivery platforms. The largest commercial opportunities are differentiated sublingual dosage forms, abuse-deterrent films, long-acting injectable systems, pediatric and geriatric-friendly products, and generic formulations that improve taste, disintegration, dose uniformity, or manufacturing efficiency.

Excipient selection must account for buprenorphine’s low dose, potent pharmacology, sublingual absorption, bitter taste, mucosal tolerability, and the risk that swallowing or gastrointestinal degradation will reduce exposure. The commercial value of an excipient platform depends less on the excipient itself than on whether it produces a clinically relevant advantage that can support formulation patents, regulatory differentiation, or lower cost of goods.

What is buprenorphine HCl and why does excipient selection matter?

Buprenorphine HCl is the hydrochloride salt of buprenorphine, a high-affinity partial mu-opioid receptor agonist used primarily for opioid use disorder and, in some markets, pain management. Buprenorphine has high potency and is administered at low milligram or sub-milligram doses, making content uniformity and blend homogeneity important manufacturing controls.

Sublingual and buccal delivery are commercially important because buprenorphine undergoes substantial first-pass metabolism when swallowed. Products must release the drug rapidly enough for transmucosal absorption while limiting the fraction that remains in the mouth or is swallowed.

Key formulation constraints include:

Attribute	Formulation implication
Low dose and high potency	Requires robust content uniformity, segregation control, and validated blend strategy
Bitter taste	Requires sweeteners, flavors, taste-masking polymers, or barrier systems
Transmucosal absorption	Excipients must support wetting, dissolution, mucosal contact, and acceptable residence time
High receptor affinity	Dose accuracy and delivery consistency are commercially important
Sublingual administration	Disintegrants and compression forces must be optimized to avoid slow dissolution
Opioid regulatory controls	Manufacturing, diversion prevention, packaging, and abuse-deterrence claims require careful design
Multiple delivery routes	Excipient strategy differs substantially between tablets, films, patches, implants, and injectables

FDA-approved buprenorphine products demonstrate that the active can be incorporated into markedly different excipient systems, including compressed tablets, rapidly dissolving sublingual tablets, polymeric films, transdermal matrices, and extended-release injectable depots [1-6].

What excipients are used in buprenorphine HCl products?

Buprenorphine HCl products use excipients selected for compression, film formation, taste control, disintegration, mucoadhesion, stabilization, or depot formation. The exact composition is product-specific and should be verified against the current FDA labeling and Inactive Ingredient Database.

Sublingual and buccal tablets

Common excipient categories include:

• Fillers and diluents, such as lactose, mannitol, microcrystalline cellulose, and inorganic salts
• Binders, including povidone and cellulose derivatives
• Disintegrants, including crospovidone, croscarmellose sodium, and sodium starch glycolate
• Lubricants, such as magnesium stearate and stearic acid
• Glidants, such as colloidal silicon dioxide
• Sweeteners and flavors, including sucrose derivatives, aspartame, sucralose, mint flavors, and other flavor systems
• pH modifiers and buffering agents
• Compression aids and soluble matrix-forming materials

The excipient system must balance fast breakup with adequate mechanical strength. Excessive hydrophobic lubricant, high compression force, or dense granulation can delay dissolution and reduce transmucosal uptake.

Sublingual films

Buprenorphine films generally rely on water-soluble or water-dispersible film-forming polymers. Relevant categories include:

• Hydroxypropyl methylcellulose
• Polyethylene oxide
• Pullulan
• Maltodextrin
• Polyvinyl alcohol
• Polyvinylpyrrolidone
• Plasticizers such as polyethylene glycol or glycerol
• Solubilizers and surfactants
• Sweeteners, flavors, and saliva-compatible coloring agents

Films can provide better unit-dose control, faster visual identification, flexible dosing, and more difficult physical manipulation than conventional tablets. Their patent value often comes from the combination of polymer ratios, drug loading, drying conditions, film thickness, residual moisture, and mechanical properties rather than from one excipient.

Transdermal systems

Transdermal buprenorphine products use pressure-sensitive adhesives, polymer matrices, backing layers, release liners, and permeation-control components. Product performance depends on:

• Buprenorphine solubility in the adhesive or matrix
• Skin permeation rate
• Adhesive wear time
• Crystallization control
• Residual drug in the patch
• Irritation and sensitization profile
• Manufacturing control over coating weight and drug distribution

Transdermal excipient opportunities are more relevant to pain products than to opioid use disorder products, where sublingual and long-acting injectable systems dominate commercial attention.

Extended-release injectable systems

Long-acting injectable buprenorphine products use in situ depot-forming or polymeric delivery systems. Atrigel-based products use a biodegradable polymer and solvent system that forms a depot after subcutaneous administration. Important formulation variables include polymer molecular weight, polymer concentration, solvent composition, particle or depot structure, injection force, syringeability, and release kinetics [5].

For injectable products, the formulation barrier is high. The excipient system must satisfy sterility, particulate, extractables and leachables, container-closure, stability, injectability, and controlled-release requirements.

What excipient strategies can differentiate a buprenorphine product?

The strongest commercial strategies focus on measurable patient or manufacturing benefits.

Taste masking and mouthfeel

Bitter taste is a major limitation for sublingual and buccal products. Taste masking can use:

• Sweetener and flavor combinations
• Ion-pairing or complexation
• Polymer coatings
• Drug-loaded microparticles
• Cyclodextrin complexes
• Lipid or resin systems
• Rapidly dissolving protective matrices

Taste masking must not materially delay buprenorphine release or reduce transmucosal uptake. A formulation that tastes better but increases swallowed drug may produce lower or more variable exposure.

Rapid dissolution

Rapid-dissolving tablets can use highly soluble fillers, porous granules, direct compression, lyophilization, or effervescent systems. Commercially useful targets include:

• Shorter residence time under the tongue
• Lower residual mass
• Reduced need to hold saliva in the mouth
• Better adherence in patients who dislike tablets
• More consistent administration in supervised settings

A rapid-dissolution claim is more defensible when linked to dissolution testing, in vivo pharmacokinetics, or a documented administration benefit.

Mucoadhesion and residence-time control

Mucoadhesive polymers can increase contact with sublingual or buccal tissue. The risk is excessive adhesion, discomfort, delayed removal, or variable dosing. A practical strategy is moderate adhesion combined with controlled hydration rather than maximum residence time.

Potential polymer platforms include hydroxypropyl cellulose, hydroxypropyl methylcellulose, carbomers, polycarbophil, sodium alginate, and polyethylene oxide. The commercial opportunity is strongest where the product can show improved dose retention without compromising comfort.

Abuse-deterrent formulation

Buprenorphine products may be diverted or manipulated. Excipient strategies can make crushing, extraction, injection, or nasal administration more difficult. Options include:

• High-strength polymer matrices
• Gel-forming excipients
• Aversion agents
• Physical barriers to powder formation
• Controlled hydration systems
• Combination products that reduce misuse incentives

An abuse-deterrent claim requires evidence under FDA’s abuse-deterrence framework. A formulation cannot be marketed as abuse-deterrent solely because it is difficult to crush or because it contains a polymer [7].

Combination with naloxone

Buprenorphine/naloxone products remain the largest commercial formulation class for office-based opioid use disorder treatment. Excipient strategy can support:

• Differential buprenorphine and naloxone release
• Taste masking for both active ingredients
• Stable film or tablet dimensions
• Reduced risk of dose segregation
• Improved dose identification
• Lower manufacturing cost

The pharmacological combination itself is not an excipient innovation, but excipient selection can support a differentiated fixed-dose product and help manage the tradeoff between sublingual bioavailability and swallowed exposure.

What formulations are protected by buprenorphine patents?

Buprenorphine patent protection has historically focused on dosage forms, delivery systems, combinations, manufacturing methods, and release profiles rather than broad composition-of-matter protection for the established active ingredient.

Formulation area	Typical patent subject matter	Commercial relevance
Sublingual tablets	Excipient ratios, dissolution, dosage uniformity, taste masking	Generic and branded tablet differentiation
Buccal films	Polymer matrix, multilayer structure, drying, drug loading, adhesion	High-value branded lifecycle management
Buprenorphine/naloxone	Ratio, release behavior, film geometry, stability, abuse resistance	Core opioid use disorder market
Depot injections	Polymer-solvent system, depot formation, release kinetics, injection device	High barrier to generic entry
Transdermal patches	Adhesive matrix, permeation control, crystallization prevention	Pain-management applications
Implants	Polymer reservoir, release rate, insertion device, removal characteristics	Long-duration adherence and diversion control
Manufacturing methods	Granulation, coating, solvent removal, film casting, sterile filling	Process patents and freedom-to-operate issues

The most defensible formulation claims usually combine composition and performance limitations. A claim directed only to a conventional excipient may be vulnerable if the excipient is well known. Claims tied to a specific polymer ratio, dissolution profile, bioavailability range, depot release curve, or manufacturing parameter are generally more commercially relevant.

What is the FDA regulatory status of buprenorphine HCl products?

FDA has approved buprenorphine products in several dosage forms and combination products. Major regulatory categories include:

Product type	Example FDA-approved product	Active ingredient status	Regulatory role
Sublingual tablet	Subutex and generic buprenorphine tablets	Buprenorphine HCl	Established reference platform
Sublingual tablet	Zubsolv	Buprenorphine HCl/naloxone HCl	Branded combination product
Buccal film	Bunavail	Buprenorphine/naloxone	Film-based opioid use disorder treatment
Sublingual film	Suboxone and generics	Buprenorphine/naloxone	Large generic and branded market
Extended-release injection	Sublocade	Buprenorphine	Monthly depot treatment
Extended-release injection	Brixadi	Buprenorphine	Weekly and monthly depot treatment
Transdermal system	Butrans	Buprenorphine	Chronic pain indication

The FDA Inactive Ingredient Database is the principal public resource for evaluating precedent for excipient use by route and dosage form [8]. Prior approval of an excipient in one route does not establish suitability for another route. An excipient used in an oral tablet may require separate toxicological and regulatory justification for sublingual, buccal, injectable, or implantable use.

When does buprenorphine lose exclusivity and what generic entry risks exist?

Buprenorphine’s original active-ingredient exclusivity has expired in the United States. Current commercial protection is concentrated in formulation, delivery-system, method-of-use, device, and manufacturing patents, along with regulatory exclusivities and product-specific litigation.

Generic entry risk differs by dosage form:

Product category	Generic entry risk	Main barrier
Conventional sublingual tablets	High	Mature technology and established excipient precedent
Sublingual films	Moderate to high	Polymer composition, bioequivalence, patents, and film manufacturing
Buprenorphine/naloxone films	Moderate	Product-specific patents and complex comparative performance
Transdermal patches	Moderate	Adhesive, permeation, and residual-drug performance
Monthly depot injections	Lower in the near term	Complex formulation, device, clinical bridging, and manufacturing
Implants	Lower	Surgical administration, device integration, and controlled-release performance

Paragraph IV risk is highest where a generic applicant can demonstrate bioequivalence using a conventional tablet or film and challenge listed formulation patents. The risk is lower for long-acting injections because generic or follow-on products may require complex pharmaceutical equivalence, device compatibility, in vitro release characterization, and additional clinical or pharmacokinetic evidence.

Orange Book listings should be analyzed at the specific reference-product level. A patent covering a buprenorphine/naloxone film does not automatically block a buprenorphine-only tablet, and a patent covering a depot injection may have no relevance to a sublingual generic [9].

Which companies compete in buprenorphine formulation markets?

The competitive landscape includes:

• Indivior, associated with Suboxone and other buprenorphine/naloxone film products
• Braeburn, associated with long-acting injectable buprenorphine products
• Alkermes, associated with extended-release injectable buprenorphine through Sublocade
• Generic manufacturers supplying buprenorphine and buprenorphine/naloxone tablets and films
• Transdermal manufacturers supplying buprenorphine patches for pain
• Contract development and manufacturing organizations with film, depot, and sterile injectable capabilities

The most attractive commercial spaces are not necessarily the largest by unit volume. Conventional tablets are easier to enter but face price compression. Films can command differentiated pricing but carry greater patent and manufacturing risk. Long-acting injectables have higher development cost and manufacturing complexity but can support recurring monthly revenue and stronger adherence positioning.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can capture value through platform technologies rather than commodity sales. Priority opportunities include:

Sublingual excipient platforms

A supplier can develop directly compressible, fast-wetting, low-moisture excipient systems optimized for low-dose opioid products. Useful performance claims include improved content uniformity, shorter disintegration time, lower tablet friability, and reduced sensitivity to lubricant concentration.

Taste-masking systems

Taste-masking technologies can target buprenorphine alone or buprenorphine/naloxone combinations. The most valuable systems maintain rapid transmucosal release while lowering bitterness during the first seconds of administration.

Film-forming systems

Ready-to-use polymer blends can reduce development time for buccal and sublingual films. Suppliers can differentiate through:

• Higher drug-loading capacity
• Lower residual solvent
• Better tear resistance
• Improved dimensional uniformity
• Controlled adhesion
• Lower drying energy
• Compatibility with continuous manufacturing

Injectable depot excipients

Biodegradable polymers, solvent systems, and suspension stabilizers have high commercial value because qualification and scale-up are difficult. A supplier with regulatory history, impurity control, and sterile manufacturing capability is better positioned than a commodity excipient producer.

Manufacturing and packaging systems

Commercial opportunities also include unit-dose packaging, child-resistant systems, moisture barriers, tamper evidence, and dispensing systems that reduce diversion. Packaging cannot replace formulation patents, but it can support compliance, product differentiation, and controlled distribution.

How strong is the buprenorphine HCl formulation patent estate?

The estate is strongest for long-acting injectable delivery, film-based products, specialized release systems, and integrated formulation-device combinations. It is weaker for conventional immediate-release sublingual tablets that use standard excipients and established manufacturing processes.

Patent strength depends on:

1. Whether claims cover the commercial product rather than a narrow laboratory embodiment.
2. Whether the patent claims excipient composition, process, performance, or all three.
3. Whether the claimed formulation can be designed around without losing bioequivalence or manufacturability.
4. Whether the patent is listed in the Orange Book.
5. Whether the product has pending Paragraph IV litigation or a settlement restricting launch.
6. Whether the patent covers the active product, a device, or an ancillary manufacturing step.

Licensing value is highest where the patent holder controls a difficult-to-reproduce polymer system, depot process, film-casting method, or drug-device combination. Commodity excipients generally have limited standalone licensing value unless they are covered by a formulation-specific composition or supported by proprietary performance data.

What should an R&D team prioritize?

A practical development sequence is:

1. Select the target route: sublingual, buccal, injectable, transdermal, or implantable.
2. Establish the required exposure and dissolution profile.
3. Screen excipient systems for taste, mucosal tolerance, and drug release.
4. Control content uniformity at the intended low dose.
5. Evaluate stability under temperature and humidity stress.
6. Test extractables, leachables, residual solvents, and elemental impurities where relevant.
7. Build around a defensible composition and process patent strategy.
8. Assess Orange Book, FDA labeling, and freedom-to-operate exposure.
9. Compare development cost against generic price erosion and branded pricing potential.
10. Select commercial packaging and manufacturing processes early.

Key Takeaways

• Buprenorphine HCl is most commercially attractive in transmucosal and long-acting delivery systems.
• Conventional sublingual tablets have high generic competition and limited formulation differentiation.
• Films offer opportunities in taste masking, dose handling, adhesion, and abuse-deterrent design.
• Long-acting injectable products have the strongest technical barriers and potentially the highest formulation value.
• Excipient patents are most durable when they combine composition, process, and measurable performance claims.
• The FDA Inactive Ingredient Database and current Orange Book listings are central to regulatory and freedom-to-operate analysis.
• Generic risk is high for standard tablets, moderate for films and patches, and lower for complex depot injections.
• Excipient suppliers should prioritize validated polymer systems, taste-masking platforms, low-dose uniformity technologies, and sterile depot materials.

FAQs

Can lactose be used in buprenorphine HCl sublingual tablets?

Lactose has precedent in oral solid dosage forms, but suitability depends on the specific formulation, dose uniformity, moisture sensitivity, taste profile, and current FDA inactive-ingredient precedent for the intended route.

Which excipients improve buprenorphine sublingual absorption?

Excipients that improve wetting, dissolution, mucosal contact, and residence time may improve delivery. Excessive adhesion or slow hydration can have the opposite effect by increasing swallowing and delaying release.

Are buprenorphine films harder to copy than tablets?

Yes. Films require control of polymer selection, drug loading, casting, drying, residual moisture, mechanical strength, adhesion, and dissolution. Those variables create more development and manufacturing barriers than conventional compressed tablets.

Do buprenorphine excipient patents create biosimilar risk?

No. Buprenorphine is a small-molecule drug, so the relevant competition is generic rather than biosimilar. Complex injectable formulations can still face follow-on product risk, but the legal pathway differs from biosimilar regulation.

Can a new excipient create market exclusivity for buprenorphine?

An excipient alone rarely creates meaningful exclusivity. Commercial protection is stronger when the excipient is part of a novel formulation, manufacturing process, release profile, delivery device, or clinically supported product advantage.

References

1. U.S. Food and Drug Administration. (2023). Subutex (buprenorphine hydrochloride) sublingual tablet prescribing information.

2. U.S. Food and Drug Administration. (2023). Suboxone (buprenorphine hydrochloride and naloxone hydrochloride) sublingual film prescribing information.

3. U.S. Food and Drug Administration. (2023). Zubsolv (buprenorphine and naloxone) sublingual tablet prescribing information.

4. U.S. Food and Drug Administration. (2023). Bunavail (buprenorphine and naloxone) buccal film prescribing information.

5. U.S. Food and Drug Administration. (2024). Sublocade (buprenorphine extended-release) injection prescribing information.

6. U.S. Food and Drug Administration. (2024). Brixadi (buprenorphine) extended-release injection prescribing information.

7. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling.

8. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.

9. U.S. Patent and Trademark Office. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.